PsiThera raised $25 million in financing led by new investors AbbVie Ventures and Lumination Capital, alongside existing backers. The funds will support development of its oral small molecule TNFα inhibitor and advance its oral TL1A inhibitors into lead optimization. Using its proprietary QUAISAR platform, which combines AI and biophysics, PsiThera aims to create effective oral therapies for immune diseases traditionally treated with injectables. This financing accelerates their progress toward clinical trials and expanding their immunology drug pipeline.
PsiThera's $25 million financing news provides context for health sector trends. For readers following health stocks, here is Pluang's market snapshot as of Nov 10, 2026 18:42 WIB: Among 150 priced health-sector US stocks, 85 rose and 56 fell today. Notable movers include ABEO at USD 2.60 with a 1-day change of +2.36% and a typical hold time of 24 days, DFTX at USD 36.18 up 2.23% with 100% buy orders, and TVTX at USD 50.50 down 2.19% with a typical hold time of 8 days.
The 2026 Verizon Data Breach Investigations Report links 61% of manufacturing breaches to third parties and 81% to internal data compromise. Manufacturers adopting Microsoft 365 Copilot should carefully manage which engineering and supplier files emp...
Soleo Health has been selected as a specialty pharmacy partner for Pasatru™ (garetosmab-grts), Regeneron's FDA-approved treatment for adults with fibrodysplasia ossificans progressiva (FOP), an ultra-rare genetic disorder. Pasatru™ is the first treat...
Opus Genetics announced its Q3 2026 financial results and significant progress in its gene therapy programs for inherited retinal diseases. Key milestones include completion of dosing in OPGx-BEST1 Cohort 2 with data expected in Q1 2027, full enrollm...
Iveco Group is exhibiting its latest products, including new light and heavy-duty vehicles powered by FPT engines, at Fenatran 2026 in São Paulo, highlighting its strong industrial and commercial presence in Latin America. The event marks the regiona...
The global paracetamol market is projected to grow from $12.05 billion in 2026 to $15.39 billion by 2032, with a CAGR of 4.12%. Growth is driven by increasing demand for pain and fever management, expanded access to over-the-counter medicines, and in...
